건강과 대안 » guidance documents http://www.chsc.or.kr 연구공동체 Mon, 13 Apr 2026 01:34:28 +0000 ko-KR hourly 1 http://wordpress.org/?v=3.5.2 [돼지독감] Pandemic (H1N1) 2009 guidance documents(WHO) http://www.chsc.or.kr/?post_type=reference&p=1286 http://www.chsc.or.kr/?post_type=reference&p=1286#comments Wed, 11 Nov 2009 15:34:40 +0000 건강과대안 http://www.chsc.or.kr/?post_type=reference&p=1286 Pandemic (H1N1) 2009 guidance documents

출처 : http://www.who.int/csr/resources/publications/swineflu/en/index.html


A

Advice on the use of masks in the community setting in Influenza A(H1N1) outbreaks
Availability of a candidate international standard for antibody to A/California/7/2009 (H1N1)v-like viruses
Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development CBER-RG2
Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development NIBRG-121
Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A
Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development: IDCDC-RG15
Availability of a candidate reassortant vaccine virus for the novel influenza A(H1N1) vaccine development IVR-153
Availability of a new candidate reassortant vaccine virus for pandemic (H1N1) 2009 virus vaccine development NIBRG-121xp
Availability of four new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 virus vaccine development IDCDC-RG18, IDCDC-RG20, IDCDC-RG22 and NIBRG-122
Availability of two new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 virus vaccine development X-181 and X-181A
Availability of vaccine potency testing reagents for pandemic (H1N1) 2009 virus vaccines

Back to top


B

Behavioural interventions for reducing the transmission and impact of influenza A(H1N1) virus: a framework for communication strategies
Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus CBER-RG2
Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus IVR-153
Biocontainment requirements for vaccine production from and quality control of the reassortant vaccine candidate viruses IDCDC-RG15, NIBRG-121 and X-179A

Back to top


C

Call to action
Case management of Influenza A(H1N1) in air transport
CDC protocol of realtime RTPCR for influenza A (H1N1)
Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development
Clean hands protect against infection
Clinical management of human infection with new influenza A (H1N1) virus: revised guidance
Considerations of influenza A(H1N1) and HIV infection
Consultation on potential risks of pandemic (H1N1) 2009 influenza virus at the human-animal interface
Countries able to perform PCR to diagnose influenza A (H1N1) virus infection in humans

Back to top


G

Gene sequences of the reassortant candidate vaccine viruses for the novel influenza A (H1N1)
Global surveillance during an influenza pandemic

Back to top


H

Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance

Back to top


I

Infection prevention and control in health care for confirmed or suspected cases of pandemic (H1N1) 2009 and influenza-like illnesses
Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care
Influenza A(H1N1) patient care checklist
Instruction on how to obtain CDC realtime RT-PCR kits for detection of influenza A(H1N1)
Instructions for shipments of pandemic (H1N1) 2009 specimens and virus isolates to WHO Collaborating Centres for influenza
Instructions for storage and transport of suspected or confirmed human and animal specimens and virus isolates of pandemic (H1N1) 2009
Instructions for transport of virus cultures (i.e. virus isolates) of candidate reassortant vaccine viruses of pandemic (H1N1) 2009 virus

Back to top


J

Joint WHO-OFFLU technical teleconference to discuss human–animal interface aspects of the current influenza A (H1N1) situation

Back to top


L

Laboratory biorisk management for laboratories handling human specimens suspected or confirmed to contain influenza A (H1N1) causing the current international epidemics

Back to top


P

Pandemic influenza preparedness and mitigation in refugee and displaced populations. WHO guidelines for humanitarian agencies.
Pandemic influenza preparedness and response
Pandemic influenza prevention and mitigation in low resource communities
Protocol for antiviral susceptibility testing by pyrosequencing

Back to top


R

Recommendations of the Strategic Advisory Group of Experts (SAGE) on Influenza A (H1N1) vaccines
Reducing excess mortality from common illnesses during an influenza pandemic.
Reducing transmission of pandemic (H1N1) 2009 in school settings

Back to top


S

Sequencing primers and protocol
Status of candidate vaccine virus development for the current Influenza A(H1N1) virus
Summary report of a High-Level Consultation: new influenza A (H1N1)

Back to top


U

Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Back to top


V

Viral gene sequences to assist update diagnostics for influenza A (H1N1)
Viral gene sequences to assist update diagnostics for influenza A (H1N1) – GenBank accession numbers

Back to top


W

WHO ad hoc scientific teleconference on the current influenza A(H1N1) situation
WHO Consultation on suspension of classes and restriction of mass gatherings to mitigate the impact of epidemics caused by the new influenza A (H1N1)
WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses
WHO Information for Laboratory Diagnosis of New Influenza A (H1N1) Virus in Humans
WHO recommendations on influenza A(H1N1) vaccines
WHO Technical Consultation on the Severity of Disease Caused by the new influenza A (H1N1) virus infections

]]> http://www.chsc.or.kr/?post_type=reference&p=1286/feed 0